Immunotherapy company acquired for >$4B & 10 more updates...👇
Want a list of segmented biopharma companies or access to our online platform? Get more info about our data and how it can help with sales and market intelligence
🎯 → Approvals
🔬 → New data
🤝 → M&A activity
AstraZeneca
🎯 FASENRA (benralizumab) received FDA approval for the treatment of children aged 6 to 11 with severe asthma.
VIIV healthcare
🎯 FDA approved Dovato (dolutegravir/lamivudine) for the treatment of HIV-1 infection in adolescents 12 years of age and older.
Inozyme Pharma
🔬 Topline data reported from Ph1/2 trials of INZ-701 in adults with ABCC6 deficiency (PXE) and ENPP1 deficiency showing sustained levels of plasma pyrophosphate (PPi) levels comparable to those observed in Inozyme’s study of healthy subjects.
Alkermes
🔬 Ph1b topline results reported from ALKS 2680 study showing improved wakefulness in patients w/ narcolepsy type 2 and idiopathic hypersomnia.
Palatin Technologies
🔬 Reported Ph3 PL9643 MELODY-1 Dry Eye Disease (DED) data at ASCRS 2024 showing multiple co-primary and multiple symptom endpoints met suggesting good safety and tolerability profile from the drug.
RAPT Therapeutics
🔬 Ph2 trial results indicate Tivumecirnon plus anti-PD-1 immunotherapy has an acceptable safety profile in CPI-experienced head and neck cancer patients. No increase in immune-related toxicity was observed compared to pembrolizumab monotherapy.
Vertex
🤝 Vertex entered into agreement to acquire Alpine Immune Sciences for $4.9B cash.
Century Therapeutics
🤝 To acquire Clade Therapeutics for $35M.
SciSparc
🤝 SciSparc to acquire AutoMax
Nuvation Bio
🤝 Nuvation Bio completes acquisition of AnHeart Therapeutics.
---
Interested in these updates? Get the full update each week → https://www.biopharmiq.com/#subscribe
Data:
April 8-12, 2024
Article History:
RF, DV (04/12/24)
Comments